The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.
M. Talpaz
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Deciphera; Exelixis; Incyte; Merck; Millennium; Novartis; Takeda; Targeted Genetics
N. P. Shah
Research Funding - ARIAD
M. W. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Celgene; Genzyme
M. J. Mauro
Research Funding - ARIAD
I. W. Flinn
Research Funding - ARIAD
S. Lustgarten
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
W. Lindmark
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
J. M. Gozgit
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
T. Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
C. D. Turner
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
F. G. Haluska
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
H. Kantarjian
Research Funding - ARIAD
J. E. Cortes
Consultant or Advisory Role - ARIAD; Novartis
Research Funding - Ambit BioSciences; ARIAD; Novartis